Compare SINT & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | PULM |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 9.4M |
| IPO Year | 2007 | 2013 |
| Metric | SINT | PULM |
|---|---|---|
| Price | $2.72 | $2.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 30.8K | ★ 43.2K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | $2,887,000.00 | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $80.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.90 | ★ 5069.93 |
| 52 Week Low | $1.72 | $1.63 |
| 52 Week High | $6.78 | $9.37 |
| Indicator | SINT | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 37.45 |
| Support Level | $2.55 | N/A |
| Resistance Level | $2.94 | $5.05 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 9.26 | 22.60 |
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).